Present state of the treatment of HIV infection;El estado actual del tratamiento de la infeccion por HIV

Medicina

Volumn 59, Issue 4, 1999, Pages 385-392

  Suarez, Claudia J ^a   Jahnke, Natalie ^a   Montaner, Julio S G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE   (Canada)

Author keywords

HIV AIDS; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOVIRIDE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC THERAPY; BLOOD TOXICITY; DRUG SAFETY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LYMPHOCYTE COUNT; NEUROTOXICITY; PANCREATITIS; PROGNOSIS; REVIEW; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TREATMENT FAILURE; TREATMENT PLANNING; VIRUS LOAD; VIRUS RESISTANCE; XEROSTOMIA;

EID: 0032714868     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Carpenter C, Fischl M, Hammer S, et al. Consensus Statement-Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA 1996; 276: 146-54.
2. Therapeutic Guidelines for the Treatment of HIV/AIDS and Related Conditions. BC Centre for Excellence in HIV/AIDS 1996, Vancouver, BC, Canada.
3. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998; 12: 279-84.
4. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-4.
5. Rhone SA, Hogg RS, Yip B, et al. Double trouble: Do dual nucleoside regimens have a role in an era of viral load-driven antiretroviral therapy? J Infect Dis 1998; 178: 662-8.
6. Carpenter C, Fischl M, Hammer S, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA 1997; 277: 1962-9.
7. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
8. Anís A, Hogg RS, Wang X, et al. The cost-effectiveness of current antiretroviral regimens. Abstract OP6.5. 4th International Congress on Drug Therapy in HIV Infection, 1998 Glasgow. AIDS 1998; 12: S1-S113.
9. Bartlett J, Chaisson R, Kerruly J, et al. HAART: One of the most cost-effective therapies of the past decade. Abstract 24380. 12th World AIDS Conference, June 1998, Geneva.
10. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
11. Clumeck N for the AVANTI Study Group: AVANTI 3. A randomized, double-blind comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/ Nelfinavir in antiretroviral naive patients. Abstract 8. 5th Conference on Retroviruses and Opportunistic Infections, Chicago III, 1998.
12. Connick E, Lederman M, Kotzin B, et al. Immunologic effects of 48 weeks of AZT/3TC/ritonavir. Abstract LB14. 5th Conference on Retroviruses and Opportunistic infections, Chicago, III, 1998.
13. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of Nevirapine, Didanosine and Zidovudine for HIV-infected patients-The INCAS Trial. JAMA 1998; 279: 930-7.
14. Tashima K, Staszewski S, Stryker R, et al. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of Efavirenz (EFV)+ Indinavir (IDV), versus EFV+zidovudine (ZDV) + Lamivudine (3TC), versus IDV+ZDV+3TC at 48 weeks (Study DMP 266-006). LB 16. 6th Conference on Retroviruses and Opportunistic infections, Chicago, III, 1998.
15. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV infected individuals following initiation of triple combination antiretroviral regimens. CMAJ 1999; 160: 659-65.
16. Montaner JSG, Montessori V, Raboud JM, et al. How low is low enough: suppression of plasma viral load below 20 copies/mL is necessary for long term virological response. Abstract 12364. Proceedings of the 12th World AIDS Conference, Geneva, 1998.
17. Fischl M, Greenberg S, Clumeck N, et al. Ziagen (Abacavir, 1592) combined with 3TC and ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naive subjects (CNAA3003). Abstract 19. 6th Conference on Retroviruses and Opportunistic infections, Chicago, III, 1998.
18. Staszewski S, Keiser P, Gathe J, et al. Ziagen/Combivir is equivalent to Indinavir/Combivir in antiretroviral therapy naive adults at 24 weeks. Abstract 20. 6th Conference on Retroviruses and Opportunistic infections, Chicago, III, 1998.
19. Katlama C, Murphy R, Johnson V, et al. The Atlantic Study: A randomized open-label study comparing two protease inhibitors-sparing antiretroviral strategies vs a standard Pl-containing regimen. Abstract 18. 6th Conference on Retroviruses and Opportunistic infections, Chicago, III, 1998.
20. Kaufmann D, Pantaleo G, Sudre P, et al. CD4 cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351-723-4.
21. Deeks S, Barbour J, Swanson M, et al. Sustained CD4 T cell response after failure of protease inhibitor based regimens: correlation between CD4 and viral load response after two years of therapy. Abstract 494. 6th Conference on Retroviruses and Opportunistic infections Chicago, 1998.
22. Cameron DW, Hsu A, Granneman GR, et al. Pharmacokinetics of ritonavir-saquinavir combination therapy. AIDS 1996; 10 (suppl 2): S16.
23. Burger DM, Hugen PWH, Prins JM, et al. Pharmacokinetics of an indinavir/ritonavir 800/100 mg BID regimen. Abstract 363. 6th Conference on Retroviruses and Opportunistic infection, Chicago III, 1998.
24. Gallant JE, Heath-Chiozzi M, Raines C, et al. Safety and efficacy of nelfinavir-ritonavir combination therapy. Abstract 394a. 5th Conference on Retroviruses and Opportunistic infections, Chicago III, 1998.
25. Havlir DV, Riddler S, Squires K, et al. Co-administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity results. Abstract 393. 5th Conference on Retroviruses and Opportunistic infections, Chicago III, 1998.
26. Opravil M for SPICE Study Team: Study of protease inhibitor combination in Europe (SPICE); saquinavir soft gelatin capsule (SQV-SGC) and nelfinavir in HIV infected individuals. Abstract 394b. 5th Conference on Retroviruses and Opportunistic infections, Chicago III, 1998.
27. Ruiz L, Bonjoch A, Paredes R, et al. A multi-center, randomized, open-label comparative trial of the clinical benefit of switching the protease inhibitor (Pl) by nevirapine (NVP) in HAART-experienced patients suffering lypodystrophy (LD). (LB14). 6th Conference on Retroviruses and use of triple drug therapy, Chicago III, 1998.
28. Havlir D, Hellman N, Petropoulos C, et al. Viral rebound in the presence of indinavir without protease inhibitor resistence. LB12. 6th Conference on Retroviruses and Opportunistic infections, Chicago III, 1998.
29. Baxter JD, Mayers DK, Wentworth DN, et al. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. (LB8). 6th Conference on Retroviruses and Opportunistic infections, Chicago III, 1998.
30. Durant J, Clevenberg P, Halfon PH, et al. Can HIV genotype determination be useful for individualized adaptation of antiretroviral therapy? The VIRADAPT French Study. AIDS 1998; 12 (S4-S16).
31. Montaner JSG, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced Human Immunodeficiency Virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV Trials Network Protocol 080. J Infect Dis 1997; 175: 6.
32. Montaner JSG, Harrigan PR, Jahnke N, et al. Multi-Drug Rescue Thepray (MDRT) for HIV-infected individuals with prior virologic failure to multiple regimens: preliminary results. Abstract P1. 4th International Congress on Drug Therapy in HIV Infection, 1998, Glasgow. AIDS 1998; 12: S1-S113.
33. Miller V, Gute P, Carlebach A, et al. Baseline resistance and virological response to Mega-HAART salvage therapies. Abstract 130. 6th Conference on Retroviruses and Opportunistic infections, Chicago III, 1998.
34. Youle M, Mocroft A, Johnson M, et al. Surrogate marker responses to multidrug combinations comprising Hydroxyurea, Efavirenz, double protease inhibitors and nucleoside analogues in protease inhibitor failures. Abstract 400. 6th Conference on Retroviruses and Opportunistic infections, Chicago III, 1998.